Biomarker Testing, Surgical Outcomes, and Adjuvant Therapy Rates Among Patients with Resected Non-Small Cell Lung Cancer (NSCLC) in the Community Setting in the United States (US), 2019–2023
Date
April 6, 2024
Explore related products in the following collection:
Abstract: JNCCN23-0676 https://jnccn.org/view/journal...
Speaker
Xiaohan Hu, PhD, MPH
Merck & Co Inc
Related Products
Improved Access through an Integrated Supportive Care Model Reduced Urgent Care Referral and Admission Rates for Patients with Gastrointestinal Malignancy
Abstract: JNCCN23-0703 https://jnccn.org/view/journal... [https://jnccn.org/view/journals/jnccn/22/2.5/article-pHSR24-167…
Real-world effectiveness of erythropoiesis-stimulating agents after luspatercept in patients with myelodysplastic syndromes: a retrospective analysis of a large healthcare claims database in the United States
Abstract: JNCCN23-0560 https://jnccn.org/view/journal... [https://jnccn.org/view/journals/jnccn/22/2.5/article-pHSR24-133…
Comparing "Apples to Apples" in Uterine Cancer: Racial Disparity and Propensity Score Matching
Abstract: JNCCN23-0718 https://jnccn.org/view/journal... [https://jnccn.org/view/journals/jnccn/22/2.5/article-pHSR24-172…
Reaching Unmet Needs of Lung Cancer Patients Through Hope Totes and Educational Meetings
Abstract: JNCCN23-0752 https://jnccn.org/view/journal... [https://jnccn.org/view/journals/jnccn/22/2.5/article-pHSR24-173…
